- A new experimental drug, Maridebart cafraglutide (MariTide), shows promise for significant weight reduction and treating obesity and type 2 diabetes.
- Clinical trial results indicate MariTide can reduce body weight by up to 20 per cent within a year, with weight loss continuing beyond 12 months.
- The drug targets similar molecules as popular weight loss jabs like Ozempic and also affects insulin release, leading to improved heart health measures.
- MariTide's once-a-month or less frequent dosing schedule could enhance patient adherence and provide sustainable, long-term weight control.
- While some mild to moderate gut-related side effects were noted, they were manageable, and researchers are now exploring the drug's further efficacy and use in other conditions.
IN FULL